×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BSGM – biosig technologies, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BSGM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
03:14 pm
bsgm
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Medium
Report
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
10/22
03:22 pm
bsgm
BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel [Yahoo! Finance]
Medium
Report
BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel [Yahoo! Finance]
10/22
03:13 pm
bsgm
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
Medium
Report
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/22
09:01 am
bsgm
Form 8-K BioSig Technologies, For: Oct 18
High
Report
Form 8-K BioSig Technologies, For: Oct 18
9/13
04:06 pm
bsgm
Form 4 BioSig Technologies, For: Sep 11 Filed by: Amato Anthony N.
Low
Report
Form 4 BioSig Technologies, For: Sep 11 Filed by: Amato Anthony N.
9/13
04:00 pm
bsgm
Form 8-K BioSig Technologies, For: Sep 11
Low
Report
Form 8-K BioSig Technologies, For: Sep 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19
37.4%
4/21 BioSig Technologies Inc (NASDAQ: BSGM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 15.6%
4/9 Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv 15.1%
6/10 BioSig Technologies Set to Join Russell 3000® Index 13.6%
3/25 WHO Officials Indicating at Least 20 Vaccines in Development in Global Race for a Cure 12.2%
2/19 BioSig Completes 100th Patient Case with PURE EP(TM) System 11.4%
5/7 BioSig Technologies Pivotal Moment [Seeking Alpha] 9.5%
5/7 Form EFFECT BioSig Technologies, 9.4%
4/24 BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 8.7%
6/6 BioSig Allowed a U.S. Patent for PURE EP™ Simulator 8.2%
4/21 BioSig Technologies Inc (NASDAQ: BSGM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 15.6%
4/9 Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv 15.1%
6/10 BioSig Technologies Set to Join Russell 3000® Index 13.6%
3/25 WHO Officials Indicating at Least 20 Vaccines in Development in Global Race for a Cure 12.2%
2/19 BioSig Completes 100th Patient Case with PURE EP(TM) System 11.4%
5/7 BioSig Technologies Pivotal Moment [Seeking Alpha] 9.5%
5/7 Form EFFECT BioSig Technologies, 9.4%
4/24 BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 8.7%
6/6 BioSig Allowed a U.S. Patent for PURE EP™ Simulator 8.2%
TOP News Decliners
3/13
Form 10-K BioSig Technologies, For: Dec 31
-14.3%
3/26 BioSig Technologies Inc (NASDAQ: BSGM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.2%
3/31 Over 35 Companies in Race to Develop Vaccine for COVID-19 Health Crises -13.4%
4/29 Form DEF 14A BioSig Technologies, For: Jun 26 -13.4%
2/20 BioSig Announces Proposed Public Offering of Common Stock -9.4%
2/19 Form 8-K BioSig Technologies, For: Feb 19 -8.7%
5/20 Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors -8.1%
4/1 BioSig Technologies Inc (NASDAQ: BSGM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.6%
5/22 Form 4 BioSig Technologies, For: May 21 Filed by: LONDONER KENNETH L -6.3%
7/31 Form 10-Q BioSig Technologies, For: Jun 30 -6.1%
3/26 BioSig Technologies Inc (NASDAQ: BSGM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.2%
3/31 Over 35 Companies in Race to Develop Vaccine for COVID-19 Health Crises -13.4%
4/29 Form DEF 14A BioSig Technologies, For: Jun 26 -13.4%
2/20 BioSig Announces Proposed Public Offering of Common Stock -9.4%
2/19 Form 8-K BioSig Technologies, For: Feb 19 -8.7%
5/20 Dr. Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors -8.1%
4/1 BioSig Technologies Inc (NASDAQ: BSGM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.6%
5/22 Form 4 BioSig Technologies, For: May 21 Filed by: LONDONER KENNETH L -6.3%
7/31 Form 10-Q BioSig Technologies, For: Jun 30 -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: